Prognostic Significance of Adipose Tissue Distribution and Metabolic Activity in PET/CT in Patients with Metastatic Colorectal Cancer

In this study, we aimed to evaluate the prognostic significance of adipose tissue distribution and metabolic activity in PET/CT predict survival patients with metastatic colorectal cancer (mCRC). The volume, density (HU), FDG uptake (standardized value (SUV)) visceral (VAT) subcutaneous (SAT) maximum tumor were measured. Subcutaneous volume-to-density ratio (SAT ratio) was calculated. median OS for SAT < −1.1 ≥ 38.5 (95% CI 31.54–45.58) 24.5 14.13–34.93) months, respectively (p = 0.05). During follow-up, 69 experienced disease progression. progression-free (PFS) 11.03 months CI: 9.11–12.95). Median PFS SUV max 11.5 9.2 7.25–11.27) 12.6 10.02–15.27) 0.14). Forty-eight received bevacizumab therapy. VAT mean (HR: 0.09; 95% 0.01–0.52, p 0.008) significantly associated receiving bevacizumab. significant parameter 0.58; 0.33–1.01, 0.05) 1.99; 1.02–3.91, 0.043). an independent factor mCRC. Higher volume is correlated longer mCRC patients.